National Health (Supply of Pharmaceutical Benefits—Under Co-payment Data and Claims for Payment) Rules 2022
9Information about supplies
Start here
Get a plain-English read of 9
Turn the raw legal text into a practical explanation grounded in National Health (Supply of Pharmaceutical Benefits—Under Co-payment Data and Claims for Payment) Rules 2022.
9 Information about supplies
(1) For the purposes of paragraphs 98AC(4)(a) and 99AAA(8)(b) of the Act, subsection (2) specifies the information that is to be given to the Secretary by an approved supplier in relation to the supply by the approved supplier of a pharmaceutical benefit. (2) The information is the following: (a) the approved supplier’s approval number allotted under section 16 of the Regulations; (b) if the approval number is to be given using the manual system and the approved supplier is an approved pharmacist: (i) the pharmacist’s name; and (ii) the address of the premises to which the approval number relates; (c) if the approval number is to be given using the manual system and the approved supplier is an approved medical practitioner: (i) the medical practitioner’s name; and (ii) the address to which the medical practitioner wishes correspondence to be sent; (d) if the approval number is to be given using the manual system and the approved supplier is an approved hospital authority: (i) the approved hospital authority’s name; and (ii) the address of the hospital to which the approval number relates; (e) if the approval number is to be given using the Claims Transmission System—the information required under Schedule 1 to be given in relation to the supply of the pharmaceutical benefit.
Note: The information must be given to the Chief Executive Medicare on behalf of the Secretary (see subsection 8(2)).